These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 6725657)

  • 21. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
    Lee S; Kim BJ; Lee YB; Lee WS
    JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of alopecia areata with squaric acid dibutylester.
    Hill ND; Bunata K; Hebert AA
    Clin Dermatol; 2015; 33(3):300-4. PubMed ID: 25889130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [DNCB therapy of alopecia areata].
    Happle R
    Z Hautkr; 1979 May; 54(10):426-9. PubMed ID: 314203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
    Kagami S; Kishi Y; Hino H
    J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
    Dall'oglio F; Nasca MR; Musumeci ML; La Torre G; Ricciardi G; Potenza C; Micali G
    J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical immunotherapy in alopecia areata.
    Singh G; Lavanya M
    Int J Trichology; 2010 Jan; 2(1):36-9. PubMed ID: 21188022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistological evaluation of alopecia areata treated with squaric acid dibutylester (SADBE).
    Johansson E; Ranki A; Reunala T; Kianto U; Niemi KM
    Acta Derm Venereol; 1986; 66(6):485-90. PubMed ID: 2433867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Controlled study of the efficacy of topical immunotherapy in alopecia areata: squaric acid versus placebo].
    Pigatto PD; Rapisarda R; Polenghi MM; Altomare GF
    G Ital Dermatol Venereol; 1987 Dec; 122(12):667-70. PubMed ID: 3329149
    [No Abstract]   [Full Text] [Related]  

  • 31. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts.
    Lee AN; Mallory SB
    J Am Acad Dermatol; 1999 Oct; 41(4):595-9. PubMed ID: 10495383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of topical immunotherapy in the treatment of alopecia areata. Quality analysis of articles published between January 1977 and January 1988 about three treatments. Reading Group.
    Naldi L; Parazzini F; Cainelli T
    J Am Acad Dermatol; 1990 Apr; 22(4):654-6. PubMed ID: 2138637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of alopecia areata with diphencyprone].
    Suditu G; Toma A; Voiculescu M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):760-2. PubMed ID: 12092234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contact immunotherapy with squaric acid dibutylester for warts [corrected].
    Iijima S; Otsuka F
    Dermatology; 1993; 187(2):115-8. PubMed ID: 8358098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of alopecia areata with dinitrochlorobenzene.
    Daman LA; Rosenberg EW; Drake L
    Arch Dermatol; 1978 Jul; 114(7):1036-8. PubMed ID: 308348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patients.
    Avitabile S; Sordi D; Garcovich S; Colonna L; De Luca A; Nasorri F; Mazzanti C; Cavani A
    J Dermatol; 2015 Jan; 42(1):98-9. PubMed ID: 25495487
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of topical sensitizers in the treatment of alopecia areata.
    Rokhsar CK; Shupack JL; Vafai JJ; Washenik K
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):751-61. PubMed ID: 9810892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.
    Zöller M; Freyschmidt-Paul P; Vitacolonna M; McElwee KJ; Hummel S; Hoffmann R
    Clin Exp Immunol; 2004 Mar; 135(3):398-408. PubMed ID: 15008971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of alopecia areata with topical sensitizers.
    Sutherland L; Laschinger M; Syed ZU; Gaspari A
    Dermatitis; 2015; 26(1):26-31. PubMed ID: 25581667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical immunotherapy in children with alopecia areata.
    Orecchia G; Malagoli P
    J Invest Dermatol; 1995 May; 104(5 Suppl):35S-36S. PubMed ID: 7738389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.